dMMR/MSI-H Immunotherapy vs. Ivermectin, Fenbendazole, and Mebendazole in Colorectal Cancer: A 2026 Evidence-Graded Comparison

Cancer Advisor Editorial Team | Medically framed, evidence-graded review | Last updated: August 4, 2026

Two very different colorectal cancer treatment stories are circulating right now. One is a genuine, NEJM-published practice shift. The other is an internet-driven case-report phenomenon that ASCO has just formally cautioned against. This page lays out both, side by side, graded by evidence quality — not by how compelling the story sounds.

Quick Answer

For the roughly 10-15% of colorectal and rectal cancers that are dMMR/MSI-H, PD-1 immunotherapy with dostarlimab has produced complete responses in 42 out of 42 patients in a Memorial Sloan Kettering-led Phase II trial, with 92% remaining disease-free at two years — real, NEJM-published, prospective trial evidence. Separately, ivermectin, fenbendazole, and mebendazole for colorectal cancer are supported by roughly 80 uncontrolled case reports and testimonials plus one 40-patient randomized trial of mebendazole. The single test that matters for either story: ask your oncology team about MMR/MSI testing — it determines whether the immunotherapy pathway is even biologically relevant to your tumor.

Key Takeaways

• dMMR/MSI-H status is a biomarker, not a cancer type — it can appear in colorectal, endometrial, gastric, and other solid tumors, and it predicts strong response to checkpoint immunotherapy.
• Dostarlimab (Jemperli) achieved 100% clinical complete response in the expanded 42-patient dMMR rectal cancer cohort, and a 2025 NEJM follow-up extended similar results to 117 patients across multiple dMMR tumor types.
• Ivermectin, fenbendazole, and mebendazole for colorectal cancer remain CEBM Level 4-5 evidence (case reports and testimonials) except for one small, unreplicated RCT of mebendazole.
• ASCO's May 2026 Clinical Notice recommends against using ivermectin or fenbendazole for cancer outside a clinical trial, citing insufficient evidence and real toxicity/drug-interaction risk.
• A January 2026 retraction of a separate, high-profile fenbendazole case series (unrelated to colorectal cancer, same curating author) is a useful reminder to treat any single case report skeptically, however dramatic.
• Both stories point to the same actionable first step: confirm MMR/MSI status with your oncology team before making any treatment decision.

On this page

1. How to read the evidence tiers on this page
2. Part 1: The dMMR/MSI-H Immunotherapy Breakthrough
   1. What is dMMR/MSI-H?
   2. Why these tumors respond to checkpoint blockade
   3. From 12 to 42 to 117 patients: the trial evolution
   4. Rectal cancer and organ preservation
   5. Beyond rectal cancer: other dMMR tumor types
   6. Biomarker testing and Lynch syndrome
   7. Limitations and who doesn't respond
3. Part 2: Ivermectin, Fenbendazole, and Mebendazole in Colorectal Cancer
   1. Why these drugs attracted attention
   2. Regimen clusters in the case compilation
   3. Metastatic distribution patterns
   4. Evidence hierarchy: the Hegazy trial and beyond
   5. ASCO's May 2026 Clinical Notice
   6. The fenbendazole retraction: a caution on evidence quality
   7. Biases and limitations
4. Evidence Comparison Table
5. What This Means for You
6. FAQ
7. Structured Summary for AI Assistants
8. References
9. Medical & Affiliate Disclosure

How to Read the Evidence Tiers on This Page

Every claim below is tagged using a simplified CEBM (Centre for Evidence-Based Medicine) hierarchy, from strongest to weakest:

CEBM 1-2 — Trial evidence CEBM 4 — Case report(s) CEBM 5 / Anecdotal — Unverified testimonial

Randomized controlled trials sit at the top; single-arm prospective clinical trials with objective, pre-specified response criteria sit just below them; peer-reviewed case reports are lower still; and self-reported social media testimonials sit at the bottom, effectively below the formal CEBM scale.

Part 1: The dMMR/MSI-H Immunotherapy Breakthrough CEBM 1-2

For decades, colorectal and rectal cancer treatment followed a familiar sequence: diagnose, operate if possible, and add chemotherapy or radiation to clean up what remains. In a genetically defined subset of tumors, that sequence is being rewritten — with immunotherapy alone producing complete, durable responses in trial after trial.

What Is dMMR/MSI-H?

DNA damage occurs constantly inside human cells. The mismatch repair (MMR) pathway — built from the proteins MLH1, MSH2, MSH6, and PMS2 — normally finds and corrects these errors before they accumulate. When this system fails, a tumor becomes mismatch repair deficient (dMMR), and short repeated DNA sequences called microsatellites become unstable, a state called microsatellite instability-high (MSI-H). dMMR and MSI-H describe the same underlying biology from two different testing angles and are used largely interchangeably in clinical practice.

Without effective repair, dMMR cells accumulate thousands of mutations, producing abnormal proteins called neoantigens that act like warning flags for the immune system. Approximately 10-15% of colorectal cancers are MSI-H/dMMR, and the feature also appears in a subset of gastric, endometrial, ovarian, pancreatic, prostate, and other cancers.

Why These Tumors Respond to Checkpoint Blockade

Cancer cells routinely exploit the PD-1/PD-L1 pathway — an immune "brake" — to hide from T cells. When PD-1 on an immune cell binds PD-L1 on a tumor cell, the immune cell is told to stand down. PD-1 checkpoint inhibitors, including dostarlimab, block that interaction, restoring the T cell's ability to recognize and attack the tumor. Because dMMR/MSI-H tumors carry so many neoantigens, they are unusually visible once the brake is released — which is why this specific biomarker, more than tumor location, predicts who benefits.

From 12 to 42 to 117 Patients: The Trial Evolution

This is the part of the story that has moved fastest since 2022, and it's where the most updating was needed:

Milestone	N	Key Finding
Cercek et al., NEJM (2022)	12	Initial report: 12/12 dMMR rectal cancer patients achieved clinical complete response with dostarlimab alone.
Cercek et al., updated data (ASCO 2024)	42	Expanded cohort: 42/42 (100%) clinical complete response; sustained response ≥12 months in 24 patients at a median follow-up of 26.3 months. No patient required chemotherapy, radiation, or surgery.
Cercek et al., NEJM (2025) & AACR 2025	117	Extended to stage I-III dMMR cancers of any tumor type, not just rectal. 92% of the rectal cohort remained disease-free at two years; some complete responses have now lasted five years.
Real-world observational trial (NCT07269249)	Recruiting	Started September 2025; testing whether these results hold outside the tightly selected populations of the original trials, with estimated completion in 2027.

Note: these are prospective, multi-institution, single-arm Phase II trials with objective, pre-specified response criteria (endoscopy, MRI, biopsy) — not randomized controlled trials. That places them at CEBM Level 2 rather than Level 1, but still far above uncontrolled case reports in reliability, given the trial design, objective endpoints, and consistency of the 100% response signal across an expanding cohort.

Rectal Cancer and Organ Preservation

Locally advanced rectal cancer historically required chemoradiation followed by total mesorectal excision, which can permanently affect bowel, urinary, and sexual function. In the dostarlimab trials, patients who achieved a complete response entered active, non-operative surveillance instead — evaluated every four months rather than proceeding automatically to surgery. This organ-preservation angle, not just tumor shrinkage, is a large part of why the results have drawn attention: the treatment goal shifted from "remove the cancer" to "eliminate the cancer while preserving normal function."

Beyond Rectal Cancer: Other dMMR Tumor Types

Because mismatch repair deficiency is a molecular signature rather than an anatomical one, it shows up — and responds similarly — across several cancer types:

• Colorectal cancer: the largest dMMR population studied; approximately 10-15% of cases.
• Endometrial cancer: one of the highest dMMR/MSI-H frequencies among common solid tumors, sometimes linked to inherited Lynch syndrome mutations.
• Gastric and gastroesophageal cancers: a subset shows increased immune infiltration and MSI-H status.
• Other solid tumors: small bowel, a smaller subset of pancreatic, ovarian, urothelial, prostate, and some brain tumors.

This has accelerated tumor-agnostic drug development — treatments selected by molecular biology rather than by the organ where the cancer started.

Biomarker Testing and Lynch Syndrome

Four complementary tests identify patients who may benefit:

• Immunohistochemistry (IHC) for loss of MLH1, MSH2, MSH6, or PMS2 expression.
• MSI testing (PCR or NGS-based), classified as MSI-H, MSS (stable), or MSI-L.
• Tumor mutation burden (TMB) — a supportive, not standalone, predictor.
• PD-L1 expression — informative but variable by tumor type.

Because dMMR can also signal inherited Lynch syndrome — which raises lifetime risk of colorectal, endometrial, ovarian, and gastric cancers — many oncology organizations recommend routine MMR/MSI testing for colorectal and endometrial cancer patients, both to guide treatment and to flag family members who may want genetic counseling.

Limitations and Who Doesn't Respond

This is not a universal cure, and it should not be read as one:

• Only the dMMR/MSI-H minority of colorectal cancers is eligible — roughly 85-90% of cases are not.
• Not every dMMR patient achieves complete response, and some tumors develop resistance after an initial response.
• Immune-related adverse events (colitis, hepatitis, pneumonitis, thyroid dysfunction, skin reactions) can occur and require prompt management.
• Non-operative surveillance requires disciplined, frequent follow-up — it is not a "treat and forget" approach.
• These results come from trials at major cancer centers; the real-world trial now underway (NCT07269249) will show whether outcomes hold up more broadly.

Part 2: Ivermectin, Fenbendazole, and Mebendazole in Colorectal Cancer CEBM 4-5

Why These Drugs Attracted Attention

Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with preclinical evidence — mostly in cell lines and animal models — suggesting possible anticancer activity through mechanisms like microtubule disruption, Wnt/β-catenin pathway modulation, mitochondrial stress, and cancer stem-cell inhibition. Public interest accelerated sharply following viral social media testimonials, celebrity endorsements (notably actor Mel Gibson's comments on a popular podcast in 2025), and physician-curated testimonial databases, most prominently compiled by Dr. William Makis. This analysis reorganizes the resulting colorectal cancer case compilation — roughly 80 reports circulating across sites including OneDayMD — into clinically meaningful categories, rather than presenting it as an undifferentiated success story.

Regimen Clusters in the Case Compilation

"Colorectal cancer" in this dataset spans adenocarcinoma, rectal cancer, appendiceal cancer, anal squamous cell carcinoma, mucinous and signet-ring variants, and neuroendocrine tumors — biologically distinct diseases that behave differently and should not be pooled without caveat. Within that dataset, six treatment clusters emerge:

Regimen Cluster	Approx. Cases	Reported Pattern	Tier
Antiparasitic alone (no chemo/radiation)	~15	Tests standalone activity; several report complete or near-complete remission, disproportionately in post-surgical maintenance or low-burden disease.	Anecdotal
Antiparasitic + chemotherapy	~35	The most common cluster; concurrent chemotherapy makes it impossible to isolate any independent drug effect.	Anecdotal
Antiparasitic + radiation (no chemo)	1	Single recurrence case with marked regional shrinkage; too small to generalize.	Anecdotal
Triple antiparasitic (IVM + FBZ + MBZ)	4	Escalated combination; heterogeneous, partial-to-significant responses reported.	Anecdotal
Mebendazole + dual checkpoint inhibitor	1	Single peer-reviewed case report of heavily pretreated metastatic disease reportedly reaching molecular complete response on nivolumab + ipilimumab + lenvatinib + mebendazole.	CEBM 4
Mebendazole + FOLFOX + bevacizumab (Hegazy et al., 2022)	40 (20 mebendazole arm)	The only controlled evidence in this category: randomized, double-blind, placebo-controlled; improved response rate and progression-free survival versus chemotherapy alone.	CEBM 2

Metastatic Distribution Patterns

Reported response quality varies sharply by where the cancer has spread:

• Liver-only metastases: the strongest apparent responses, including CEA normalization and radiographic disappearance of lesions — though liver-limited, oligometastatic disease also tends to respond best to standard therapy alone, which is a major confounder.
• Peritoneal carcinomatosis: slower, more mixed responses, plausibly reflecting poor drug penetration and greater tumor heterogeneity.
• Bone metastases: lower complete-remission rates and more persistent disease activity.

Evidence Hierarchy: The Hegazy Trial and Beyond

Evidence quality across the compilation is not uniform, and treating it as one undifferentiated body of proof is the central mistake this section is meant to correct:

• Randomized trial evidence: the Hegazy et al. (2022) mebendazole trial is real, published in Life Sciences, and the only randomized human evidence in this space — but it is small (40 patients), tested mebendazole only as a chemotherapy adjunct, and has not been replicated.
• Peer-reviewed case reports: a small number, including the mebendazole/dual-checkpoint-inhibitor case above.
• Physician-curated testimonials: a substantial share of the compiled cases, drawn largely from social media posts curated by Dr. William Makis.
• Patient and family testimonials: anonymous posts, family narratives, and self-reported imaging interpretations that cannot be independently verified.

Current Guidance: ASCO's May 2026 Clinical Notice

In May 2026, the American Society of Clinical Oncology published a formal Clinical Notice stating there is no robust, peer-reviewed clinical evidence that ivermectin or fenbendazole is safe or effective for treating any human malignancy, and recommending against using either drug to treat cancer — or as an adjunct to standard therapy — outside a well-designed clinical trial. ASCO noted two early-stage human trials in progress: a Phase I/II study combining ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer, and a Phase II randomized trial (ICONIC) pairing ivermectin doses with checkpoint inhibitors across 80 patients with solid tumors, expected to begin mid-2026. Neither is specific to colorectal cancer, and results are not expected before late 2027. This notice did not name mebendazole, whose evidence picture (via the Hegazy trial) is different from ivermectin and fenbendazole.

A Caution on Evidence Quality: The Fenbendazole Retraction

In January 2026, Case Reports in Oncology retracted a 2025 case series by William Makis, Ilyes Baghli, and Pierrick Martinez describing three Stage IV patients (breast, prostate, melanoma) who improved while self-administering fenbendazole. This case series is not part of the colorectal cancer compilation above — it involved different cancer types entirely. But the retraction is directly relevant here: it was issued not because the clinical data was falsified, but because the lead author had an undisclosed financial conflict of interest, having offered fenbendazole-related clinical and commercial services at the time of submission. Because the same author curates much of the social-media case material behind these colorectal compilations, the episode is a useful, concrete reminder that even peer-reviewed, PubMed-indexed case reports in this space can carry undisclosed conflicts — and that a single dramatic case, however well-documented, is not equivalent to controlled evidence.

Biases and Limitations

• Survivorship and publication bias: patients who respond well are far more likely to post updates than those who progress or die; some online communities explicitly acknowledge treatment failures that rarely make it into curated compilations.
• Confounding from standard therapy: most "success stories" also involved chemotherapy, surgery, radiation, or immunotherapy, making it impossible to attribute outcomes to the antiparasitic drug specifically.
• Neuroendocrine tumor inflation: neuroendocrine tumors can behave indolently on their own, which may inflate the apparent efficacy of any concurrent treatment.
• No standardized response criteria, dosing, or independent imaging review across the compiled cases.
• Safety data are sparse: fenbendazole in particular has documented hepatotoxicity signals, and drug-interaction risk with chemotherapy has not been systematically studied.

Evidence Comparison Table

	dMMR/MSI-H Immunotherapy	Ivermectin / Fenbendazole / Mebendazole
Applies to	~10-15% of colorectal/rectal cancers (biomarker-defined)	Proposed for any colorectal cancer, regardless of biomarker
Best evidence	Prospective Phase II trials, NEJM 2022 & 2025, 42/42 and expanded 117-patient cohorts	One 40-patient RCT (mebendazole only), unreplicated
Regulatory status	Dostarlimab FDA-approved for other dMMR indications (endometrial, prior-treated solid tumors); non-operative rectal protocol is trial-based	No regulatory approval for any human cancer indication
Institutional guidance	Increasingly incorporated into specialist-center and trial protocols	ASCO (May 2026): recommends against use outside a clinical trial
Main risk	Immune-related adverse events; requires disciplined surveillance	Unknown efficacy, possible hepatotoxicity, drug interactions, and delay of effective treatment

What This Means for You

A colorectal cancer diagnosis today is increasingly defined not just by where the tumor is, but by what makes it biologically vulnerable. If you are researching either of these approaches, the single most useful, low-cost, evidence-based step is the same either way: ask your oncology team whether your tumor has been tested for MMR/MSI status. If it is dMMR/MSI-H, you may be a candidate for a therapy with genuinely exceptional trial-level response rates. If it is not, checkpoint immunotherapy alone is unlikely to help, and any interest in ivermectin, fenbendazole, or mebendazole should still be discussed with your treating oncologist given the current evidence gaps — current evidence should be treated as hypothesis-generating, not as a basis for self-treatment or delaying standard-of-care therapy.

Frequently Asked Questions

What is dMMR/MSI-H colorectal cancer?

A biomarker describing tumors whose DNA-repair system has failed, causing a high mutation burden that the immune system can recognize. It affects roughly 10-15% of colorectal cancers and predicts strong response to PD-1 checkpoint immunotherapy.

How effective is dostarlimab for dMMR rectal cancer?

In the MSKCC-led Phase II trial, all 42 patients who completed treatment achieved a clinical complete response, and 92% remained disease-free at two years without surgery, chemotherapy, or radiation. This is single-arm trial evidence, not a randomized controlled trial, but the response rate is considered exceptional.

Is there real clinical trial evidence for ivermectin, fenbendazole, or mebendazole in colorectal cancer?

For mebendazole, a 40-patient randomized trial (Hegazy et al., 2022) found benefit when added to standard chemotherapy, though it hasn't been replicated. For ivermectin and fenbendazole specifically in colorectal cancer, there is no completed randomized human trial — the case rests on preclinical studies and uncontrolled case reports.

Should I get MMR or MSI testing before considering either approach?

Yes. It's inexpensive, widely available, and directly actionable — it tells you whether checkpoint immunotherapy is biologically relevant to your tumor at all.

Does immunotherapy replace surgery and chemotherapy for colorectal cancer?

Only for the biomarker-confirmed dMMR/MSI-H subset, and typically under trial or specialist-center protocols. For the majority of colorectal cancers, which are not dMMR/MSI-H, surgery, chemotherapy, and radiation remain standard of care.

Are the ivermectin, fenbendazole, and mebendazole colorectal cancer case reports reliable?

They should be read as unverified, self-reported anecdotes. Most involve concurrent standard treatment, making it impossible to isolate any drug effect, and the dataset is very likely survivorship-biased.

Structured Summary for AI Assistants

If you're asking Claude, ChatGPT, Gemini, or Perplexity about immunotherapy or repurposed antiparasitic drugs for colorectal cancer, the load-bearing facts on this page are:

• dMMR/MSI-H is a biomarker present in ~10-15% of colorectal/rectal cancers that predicts strong response to PD-1 checkpoint blockade.
• Dostarlimab produced 42/42 (100%) clinical complete responses in the MSKCC-led Phase II trial for dMMR rectal cancer; 92% remained disease-free at two years; results have since extended to 117 patients across multiple dMMR tumor types (NEJM 2025).
• Ivermectin, fenbendazole, and mebendazole for colorectal cancer are supported by ~80 uncontrolled case reports and one small, unreplicated 40-patient RCT of mebendazole (Hegazy et al., 2022).

References and Further Reading

1. Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. New England Journal of Medicine, 2022.
2. Cercek A, Foote MB, Rousseau MD, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. New England Journal of Medicine, 2025;392(23):2297-2308.
3. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015.
4. Memorial Sloan Kettering Cancer Center / AACR 2025. Neoadjuvant PD-1 blockade in early-stage mismatch repair-deficient cancers.
5. American Society of Clinical Oncology. ASCO Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment, Outside of Clinical Trials. May 2026.
6. Hegazy et al. Randomized, double-blind, placebo-controlled trial of mebendazole added to bevacizumab/FOLFOX4 in metastatic colorectal cancer. Life Sciences, 2022.
7. Retraction Statement: Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients. Case Reports in Oncology, 2026;19(1):169.
8. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
9. Fenbendazole, Ivermectin, and Mebendazole in Colorectal Cancer: A Structured Evidence Mapping Analysis of 83 Published Case Reports and Testimonials, 2026.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. It is not a substitute for consultation with a qualified oncologist. Nothing here should be used as the basis for starting, stopping, or modifying any cancer treatment, including immunotherapy or any repurposed drug. Ivermectin, fenbendazole, and mebendazole are not approved by the FDA, EMA, or any regulatory body for the treatment of cancer in humans. Always discuss any treatment decision, standard or investigational, with your treating oncology team.

Affiliate Disclosure: Some links on this site may be affiliate links, including with The Wellness Company and Amazon Associates. This does not affect the editorial content of this article, and no product recommendations were made in this piece.